PsychedelicNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy

Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. The approval marks the first known, legal medical exemption for psilocybin use in Canada since the compound became illegal in the country in 1974. A recent article discussing this anticipates more applications through the exemption process and quotes one of the applicants, Laurie Brooks, on the approval, who stated, “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgment of the pain and anxiety that I have been suffering with means a lot to me, and I am feeling quite emotional . . . as a result. I hope this is just the beginning and that soon all Canadians will be able to access psilocybin for therapeutic use, to help with the pain they are experiencing without having to petition the government for months to gain permission.”

To view the full article, visit http://ibn.fm/bFibA

About Cybin Corp.

Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21

NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs

NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined progress across its clinical programs,…

4 weeks ago

PsychedelicNewsBreaks – NextPlat Corp. (NASDAQ: NXPL, NXPLW) Reports Q3 2025 Results Highlighted by Cost Reductions and Improving Healthcare Trends

NextPlat (NASDAQ: NXPL, NXPLW) reported third-quarter 2025 results showing consolidated revenue of about $13.8 million…

1 month ago